We conducted the most extensive Italian retrospective study to date, providing valuable insights into the comparative effectiveness of ZA and DMAB in combination with ET plus CDK4/6i, which represents the standard-of care therapy for patients with HR+/HER2-aBC. This evidence concerns the gene HR and aneurysmal bone cyst.